Clorox (NYSE:CLX) Price Target Lowered to $109.00 at Citigroup

Clorox (NYSE:CLX) had its target price cut by Citigroup from $120.00 to $109.00 in a research report released on Wednesday morning, Marketbeat Ratings reports. They currently have a neutral rating on the stock.

A number of other research firms have also recently commented on CLX. Bank of America decreased their target price on shares of Clorox from $135.00 to $125.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 8th. Zacks Research raised shares of Clorox from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 26th. TD Cowen decreased their price objective on shares of Clorox from $120.00 to $117.00 and set a “hold” rating on the stock in a research report on Wednesday, October 1st. Wells Fargo & Company dropped their target price on shares of Clorox from $125.00 to $117.00 and set an “equal weight” rating for the company in a report on Tuesday, November 4th. Finally, Rothschild & Co Redburn cut their price target on Clorox from $120.00 to $115.00 and set a “neutral” rating for the company in a research note on Wednesday, November 5th. One analyst has rated the stock with a Buy rating, thirteen have assigned a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Clorox currently has a consensus rating of “Reduce” and an average target price of $125.00.

Clorox Price Performance

Shares of Clorox stock opened at $101.44 on Wednesday. The stock’s fifty day moving average is $108.77 and its 200 day moving average is $118.59. Clorox has a one year low of $98.20 and a one year high of $165.00. The company has a debt-to-equity ratio of 18.01, a quick ratio of 0.50 and a current ratio of 0.76. The stock has a market cap of $12.37 billion, a P/E ratio of 15.93, a P/E/G ratio of 0.50 and a beta of 0.57.

Clorox (NYSE:CLX) last issued its quarterly earnings results on Monday, November 3rd. The company reported $0.85 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.07. Clorox had a return on equity of 358.39% and a net margin of 11.68%.The business had revenue of $1.43 billion during the quarter, compared to analysts’ expectations of $1.41 billion. During the same quarter in the prior year, the business posted $1.86 earnings per share. The business’s quarterly revenue was down 18.9% on a year-over-year basis. Clorox has set its FY 2026 guidance at 5.950-6.300 EPS. Sell-side analysts anticipate that Clorox will post 7.15 earnings per share for the current year.

Clorox Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Wednesday, January 28th will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 4.9%. The ex-dividend date of this dividend is Wednesday, January 28th. Clorox’s dividend payout ratio is 77.86%.

Insider Buying and Selling at Clorox

In other news, Director Pierre R. Breber bought 4,000 shares of Clorox stock in a transaction dated Friday, November 21st. The shares were purchased at an average cost of $104.13 per share, with a total value of $416,520.00. Following the completion of the acquisition, the director owned 13,000 shares of the company’s stock, valued at $1,353,690. This trade represents a 44.44% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.63% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Clorox

Institutional investors have recently added to or reduced their stakes in the company. Invesco Ltd. raised its holdings in shares of Clorox by 138.3% during the 2nd quarter. Invesco Ltd. now owns 3,245,175 shares of the company’s stock worth $389,648,000 after acquiring an additional 1,883,465 shares in the last quarter. Norges Bank bought a new stake in Clorox in the second quarter worth $190,429,000. Van ECK Associates Corp raised its stake in Clorox by 93.9% during the third quarter. Van ECK Associates Corp now owns 2,709,972 shares of the company’s stock valued at $334,139,000 after purchasing an additional 1,312,471 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its position in Clorox by 218.4% during the second quarter. Arrowstreet Capital Limited Partnership now owns 1,249,127 shares of the company’s stock valued at $149,983,000 after purchasing an additional 856,873 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC bought a new position in Clorox during the second quarter valued at $71,856,000. Hedge funds and other institutional investors own 78.53% of the company’s stock.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.